Onconetix, Inc. (ONCO)
$0.56-5.08%Close
SELLCRISIS · day 10
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $187,056
- Beta
- 2.61
- P/E (TTM)
- -0.06
- Short % float
- 348.18%
- Days to cover
- 1.0
- SI change
- +261.8%
- 1W
- -15.15%
- 1M
- -12.50%
- vs SPY 1W
- -15.01%
- vs SPY 1M
- -15.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 28
- GROWTH
- 43
- GARP
- 6
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC-55.2%
REV YoY-
ROE-92.0%
EPS YoY-
ROA-62.1%
GROSS80
OP-1266
NET-1579
[VALUATION]
P/E TTM-0.06
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.09
P/FCF-
EV/EBITDA0.38
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E1.39
ALTMAN Z-
CURR RATIO2.21
ND/EBITDA-
BETA2.61
Company news
FAQ
- What is LOPJLB’s current signal on ONCO?
- LOPJLB’s latest quantitative signal on Onconetix, Inc. (ONCO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ONCO in?
- Onconetix, Inc. (ONCO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Onconetix, Inc. (ONCO) do?
- Onconetix, Inc. operates as a biotechnology and pharmaceutical firm, committed to pioneering and bringing to market innovative treatments aimed at resolving critical health issues worldwide. The company's product lineup includes Entadfi, an FDA-cleared, once-daily oral medication. This prescription drug combines finasteride and tadalafil to manage benign prostatic hyperplasia (BPH). In its deve…